Thomasville National Bank Acquires 385,556 Shares of GSK plc (NYSE:GSK)

Thomasville National Bank increased its stake in GSK plc (NYSE:GSK - Free Report) by 78.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 876,997 shares of the pharmaceutical company's stock after purchasing an additional 385,556 shares during the period. GSK makes up 2.5% of Thomasville National Bank's holdings, making the stock its 12th biggest holding. Thomasville National Bank's holdings in GSK were worth $33,975,000 as of its most recent filing with the SEC.

Several other large investors have also bought and sold shares of GSK. Sierra Ocean LLC acquired a new stake in GSK in the fourth quarter valued at about $32,000. Parkside Financial Bank & Trust lifted its stake in shares of GSK by 470.1% in the fourth quarter. Parkside Financial Bank & Trust now owns 992 shares of the pharmaceutical company's stock worth $34,000 after acquiring an additional 818 shares during the period. Lee Danner & Bass Inc. bought a new stake in GSK in the fourth quarter worth approximately $39,000. Bank Julius Baer & Co. Ltd Zurich bought a new position in shares of GSK during the 4th quarter worth approximately $40,000. Finally, Atala Financial Inc bought a new position in shares of GSK during the 4th quarter worth approximately $45,000. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Stock Performance

Shares of GSK stock traded down $1.67 during trading on Friday, reaching $40.82. 7,658,630 shares of the company's stock traded hands, compared to its average volume of 4,876,320. The company has a market capitalization of $83.66 billion, a P/E ratio of 25.67, a PEG ratio of 1.12 and a beta of 0.52. The company has a current ratio of 0.78, a quick ratio of 0.52 and a debt-to-equity ratio of 1.12. The firm's 50-day moving average is $38.09 and its 200 day moving average is $36.67. GSK plc has a 1 year low of $31.72 and a 1 year high of $44.67.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, topping analysts' consensus estimates of $1.08 by $0.05. The business had revenue of $10.06 billion for the quarter, compared to analyst estimates of $7.52 billion. GSK had a net margin of 8.13% and a return on equity of 48.59%. GSK's revenue was up 2.1% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.43 EPS. Equities research analysts expect that GSK plc will post 4.14 EPS for the current year.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 10th. Stockholders of record on Friday, May 16th will be given a dividend of $0.4216 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $1.69 annualized dividend and a dividend yield of 4.13%. This is a boost from GSK's previous quarterly dividend of $0.39. GSK's dividend payout ratio (DPR) is 86.60%.

Analyst Upgrades and Downgrades

GSK has been the topic of a number of research reports. Hsbc Global Res raised GSK to a "strong sell" rating in a research report on Monday, April 28th. Wall Street Zen lowered GSK from a "buy" rating to a "hold" rating in a research report on Friday, May 30th. BNP Paribas initiated coverage on GSK in a research report on Tuesday, April 15th. They set a "neutral" rating and a $35.25 target price for the company. Finally, Berenberg Bank reaffirmed a "hold" rating on shares of GSK in a research report on Tuesday, June 3rd. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.